down arrow

Immunome, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45257U1088
USD
20.09
3 (17.55%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Vaxart, Inc.
Century Therapeutics, Inc.
Immunome, Inc.
Aadi Bioscience, Inc.
Sonnet BioTherapeutics Holdings, Inc.
Armata Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Theseus Pharmaceuticals, Inc.
Cyteir Therapeutics, Inc.
PepGen Inc.
Omega Therapeutics, Inc.
Why is Immunome, Inc. ?
1
Negative results in Jun 25
  • OPERATING CASH FLOW(Y) Lowest at USD -178.69 MM
  • DEBT-EQUITY RATIO (HY) Highest at -98 %
  • DEBTORS TURNOVER RATIO(HY) Lowest at 0 times
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 64.13%, its profits have risen by 26.3%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Immunome, Inc. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Immunome, Inc.
48.38%
0.18
78.75%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
92.00%
EBIT Growth (5y)
-275.68%
EBIT to Interest (avg)
-150.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.29
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.59
EV to EBIT
-2.59
EV to EBITDA
-2.63
EV to Capital Employed
-46.79
EV to Sales
43.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-55.69%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company
NET PROFIT(HY)

Higher at USD -85.04 MM

ROCE(HY)

Highest at -81.2%

RAW MATERIAL COST(Y)

Fallen by -14.94% (YoY

NET SALES(Q)

Highest at USD 4.01 MM

OPERATING PROFIT MARGIN(Q)

Highest at -1,139.68 %

EPS(Q)

Highest at USD -0.5

-5What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -178.69 MM

DEBT-EQUITY RATIO (HY)

Highest at -98 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

Here's what is working for Immunome, Inc.
Net Sales
At USD 4.01 MM has Grown at 46.83%
over average net sales of the previous four periods of USD 2.73 MM
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Net Profit
Higher at USD -85.04 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Profit
At USD -85.04 MM has Grown at 48.65%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Net Sales
Highest at USD 4.01 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit Margin
Highest at -1,139.68 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

EPS
Highest at USD -0.5
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by -14.94% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Immunome, Inc.
Operating Cash Flow
Lowest at USD -178.69 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debt-Equity Ratio
Highest at -98 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."